Supply security for medical radionuclides - additions 2020 Supplement to RIVM Reports 2019-0101 2017-0063 and 2018-0075 RIVM letter report 2020-0171 L.P. Roobol | C.E.N.M. Rosenbaum | I.R. de Waard Supply security for medical radionuclides - additions 2020 Supplement to RIVM reports 2019-0101 2017-0063 and 2018-0075 RIVM letter report 2020-0171 L.P. Roobol | C.E.N.M. Rosenbaum | I.R. de Waard RIVM letter report 2020-0171 Colofon © RIVM 2020 Parts of this publication may be reproduced, provided acknowledgement is given to the National Institute for Public Health and the Environment (RIVM), stating the title and year of publication. DOI 10.21945/RIVM-2020-0171 L. Roobol (author), RIVM C. Rosenbaum (author), RIVM I. de Waard (author), RIVM Contact: Lars Roobol Safety\Measuring and Monitoring
[email protected] This study was commissioned by the Ministry of Health, Welfare and Sport within the framework of ad-hoc questions for policy support Published by: National Institute for Public Health and the Environment, RIVM PO Box 1 3720 BA Bilthoven The Netherlands www.rivm.nl/en Page 2 of 77 RIVM letter report 2020-0171 Synopsis Guaranteed supply of medical radionuclides – additions 2020 RIVM has carried out additional research into the guaranteed supply of diagnostic and therapeutic radionuclides for the Netherlands. Radioactive substances can be used for making a diagnosis. There are also radioactive substances that can treat various sorts of cancer, or serve as pain relief, the so-called therapeutic radio-isotopes. Together, these substances are called medical radionuclides. Most of these medical isotopes are made in Europe, in six nuclear reactors, one of which is located in the Netherlands (the HFR).